CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Calimmune, Inc. |
Geoff Symonds |
Disease Team Research I |
GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE |
$8,278,722 |
| Stanford University |
Dr. Gary Steinberg |
Disease Team Research I |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Disease Team Research I |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$5,694,308 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Disease Team Research I |
Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
| University of California, Los Angeles |
Dr. Irvin SY Chen |
Disease Team Research I |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
| ViaCyte, Inc. |
Allan Robins |
Disease Team Research I |
Cell Therapy for Diabetes |
$0 |
| Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Research I |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
| University of California, San Francisco |
Dr. Mitchel S Berger |
Disease Team Research I |
Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
| University of Southern California |
Mark Salman Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
| University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
| University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
| Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| University of California, Los Angeles |
Bennett G Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
| Stanford University |
Professor Helen M. Blau PhD |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| Cal State Univ, Long Beach |
Dr. Lisa S Klig |
Bridges |
CIRM Stem Cell Biotechnology Training Program |
$2,919,901 |
| Cal State Fullerton |
Dr. Nilay V Patel |
Bridges |
Bridges to Stem Cell Research, Therapy and Careers: A Talent Development Program for Training Diverse Undergraduates for Careers in Regenerative Medicine |
$2,809,646 |
| California State University, Channel Islands |
Dr. Nitika S Parmar |
Bridges |
CIRM Graduate Student Training Grant for the Implementation of a Stem Cell Technology and Lab Management Program: Training in Stem Cell Sciences and Regenerative Medicine |
$2,925,187 |
| San Diego State University Foundation |
Ralph Feuer |
Bridges |
Bridges to Stem Cell Research Internship Program |
$2,934,578 |
| California State University San Marcos Corporation |
Dr. Bianca Romina Mothé |
Bridges |
CIRM Bridges to Stem Cell Research and Therapy Training Grant |
$2,936,474 |
| Brain Mapping Foundation |
Dr. Vicky Yamamoto PhD |
Conference II |
22nd Annual Neurotech Convention of SBMT; Biotech, Cell-Tech, Pharma Tech and Medtech |
$50,000 |
| SynGAP Research Fund |
Laura Bermingham |
Conference II |
2024 SynGAP Research Fund/SLC6A1 Connect/Cure GABA-A Variants International Scientific Symposium and Family Conference |
$37,500 |
| American Institute of Chemical Engineers (AIChE) |
Evan Flach |
Conference II |
2024 Bioengineering & Translational Medicine Conference |
$19,500 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Conference II |
Gene Therapy Initiative 1st Annual Symposium |
$27,500 |
| Biomedical Engineering Society |
John Falcioni |
Conference II |
2025 BMES-CMBE Annual Meeting: Cell Engineering for Mechanomedicine and Rejuvenation |
$25,000 |
| Salk Institute for Biological Studies |
Dr. Fred H Gage |
Conference II |
Cell Symposia: Engineering development and disease in organoids |
$50,000 |
| City of Hope, Beckman Research Institute |
Fouad R Kandeel |
Conference II |
2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$20,000 |
| University of California, Irvine |
Dr. Brian J. Cummings |
Conference II |
University of California, Irvine Conference on Concussion, TBI, and CTE in Athletes and Veterans |
$31,558 |
| Lineage Cell Therapeutics, Inc. |
Ioana C Hone |
Conference II |
The 2nd Annual Spinal Cord Injury Investor Symposium (“2nd SCIIS”) |
$50,000 |
| University of California, San Francisco |
Professor Jeffrey Charles Lotz |
Conference II |
2024 Center for Dental, Oral, & Craniofacial Tissue & Organ Regeneration (C-DOCTOR) Annual Spring Conference |
$24,415 |
| Stanford University |
Dr. Everett H. Meyer |
Conference II |
Cellular Immune Tolerance Symposium |
$39,498 |
| The Regents of the University of California on behalf of its Riverside Campus |
Susan Hackwood |
Conference II |
National Science Policy Symposium: Local to Global Innovation |
$48,068 |
| Stanford University |
Dr. Joseph C. Wu |
Conference II |
Stanford Drug Discovery Symposium 2024 |
$15,000 |
| University of California, San Diego |
Adam Engler |
Conference II |
BIC 2024 – 24th Annual UC Systemwide Symposium on Bioengineering at UC San Diego |
$50,000 |
| University of California, Los Angeles |
Mark Wisniewski |
Conference II |
Los Angeles Bioscience Ecosystem Summit Twenty 24 (LABEST 24) |
$50,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Conference II |
ALSP Community Conference: Insights and Potential of Cell-Based Therapies for the Treatment of Leukodystrophies |
$45,800 |
| University of California, Berkeley |
Dr. Regis Kelly |
Conference II |
Immunotherapy of Brain Disorders |
$8,376 |
| Adjuvant Partners, LLC |
Edmund Morrie Ruffin |
Conference II |
CTx Commercialization Leadership Forum |
$50,000 |